These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28017775)

  • 1. The network of immunosuppressive pathways in glioblastoma.
    Mangani D; Weller M; Roth P
    Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive mechanisms in glioblastoma.
    Nduom EK; Weller M; Heimberger AB
    Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii9-vii14. PubMed ID: 26516226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma-derived mechanisms of systemic immunosuppression.
    Waziri A
    Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
    Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
    Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the treatment of glioblastoma.
    Thomas AA; Ernstoff MS; Fadul CE
    Cancer J; 2012; 18(1):59-68. PubMed ID: 22290259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for glioma: promises and challenges.
    Han SJ; Zygourakis C; Lim M; Parsa AT
    Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
    Mirzaei R; Sarkar S; Yong VW
    Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.
    Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA
    World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
    Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA
    Elife; 2020 Feb; 9():. PubMed ID: 32014107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
    Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
    Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Advances in Immunotherapy for Glioblastoma.
    Mende AL; Schulte JD; Okada H; Clarke JL
    Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Neuro-Oncology.
    Majd N; Dasgupta P; de Groot J
    Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering challenges for brain tumor immunotherapy.
    Lyon JG; Mokarram N; Saxena T; Carroll SL; Bellamkonda RV
    Adv Drug Deliv Rev; 2017 May; 114():19-32. PubMed ID: 28625831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.